Merck & Co., Inc. (MRK) · Oct 29, 2026 · Earnings
Beat — Non-GAAP EPS $2.49 vs ~$2.1 consensus
Merck earnings beat consensus on sales and adjusted EPS, while QLEX and Winrevair support a higher 2026 outlook despite margin pressure.
Merck is in the middle of an expensive transition: it is using new launches, KEYTRUDA QLEX and large acquisitions to broaden growth before the eventual loss of exclusivity pressure on KEYTRUDA. Its recent strategy has emphasized replacing concentration in KEYTRUDA with a wider oncology and specialty-medicine pipeline, including Terns and Cidara assets.
The quarter cleared expectations by a wide margin. Sales reached $18.085 billion versus published estimates around $17.3 billion, while non-GAAP EPS was $2.49 versus consensus near $2.1. That is a genuine earnings beat, not simply a favorable comparison with last year: sales rose 5%, although adjusted EPS still declined 3% year over year. The filing states, “For the third quarter of 2026, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.04 and non-GAAP EPS was $2.49.”
| Figure | 3Q26 | 3Q25 | Consensus / prior guide |
|---|---|---|---|
| Sales (Financial Highlights) | $18,085M (+5%) | $17,276M | ~$17,300M consensus |
| Non-GAAP EPS (Financial Highlights) | $2.49 (-3%) | $2.58 | ~$2.10 consensus |
| KEYTRUDA / QLEX sales (Product sales) | $8,601M (+6%) | $8,147M | |
| WINREVAIR sales (Product sales) | $694M (+93%) | $360M | |
| Gross margin (Quarterly results) | 72.9% | 77.7% | |
| FY sales outlook (Updated outlook) | $66.8B-$67.3B | $66.3B-$67.3B prior | |
| FY non-GAAP EPS outlook (Updated outlook) | $2.77-$2.82 | $2.66-$2.76 prior |
The growth engine is starting to diversify. KEYTRUDA QLEX contributed $830 million, while WINREVAIR sales nearly doubled to $694 million; Gardasil rose 14%, WELIREG rose 56%, and newly acquired OHTUVAYRE contributed $184 million. The important nuance is that standalone KEYTRUDA sales fell 5% in the quarter, so the broader KEYTRUDA franchise grew because QLEX is beginning to offset that decline. The filing says, “Sales of KEYTRUDA QLEX were $830 million.” 〔0〕
Management raised the outlook, but not because the cost base suddenly improved. The sales range's floor increased by $500 million and the adjusted EPS range moved up, helped by a lower expected tax rate and foreign exchange. However, the operating-expense range also rose, gross margin fell sharply, and Merck added a previously unmodeled $400 million SciBrunch charge. The filing says, “The charge related to SciBrunch was not previously included in the outlook.” 〔1〕
The underlying business is better than the headline EPS decline, but still costly to build. Non-GAAP SG&A increased 10%, non-GAAP R&D increased 13%, and higher interest expense weighed on results. Gross margin dropped from 77.7% to 72.9%, primarily because of amortization, restructuring and production costs. The filing states, “Gross margin was 72.9% for the third quarter of 2026 compared with 77.7% for the third quarter of 2025.” 〔2〕
Bottom line: This is a clear earnings beat and a meaningful step forward in Merck's post-KEYTRUDA diversification story. The stronger outlook matters, but the business is buying that growth with heavier R&D, acquisition charges and lower margins.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!